Risks for NEOGENOMICS INC (NEO)

Here are some interesting risks from the recent filings of NEOGENOMICS INC. Our algorithms work hard to highlight risks unique to this company.

We may incur greater costs than anticipated, which could result in sustained losses.

We may fail to protect our facilities, which could have a material adverse effect on our business, results of operations and financial condition.

If we were required to conduct additional clinical trials prior to continuing to sell our current tests or launching any other tests we may develop, those trials could result in delays or failure to obtain necessary regulatory approvals, which could harm our business.

If any securities analyst downgrades our common stock or our sector, the price of our common stock could be negatively affected.

We may incur greater costs than anticipated, which could result in sustained losses.